^
    12ms
    A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review (PubMed, Zhongguo Fei Ai Za Zhi)
    In this article, we reported a case of NSCLC patient with a rare gene compound mutation EGFR L833V/H835L, who responded to Afatinib in combination with Anilotinib treatment well after 5 months of treatment, and computed tomography (CT) showed shrinkage of lung lesions. Meanwhile, we also compiled previously reported NSCLC patients with EGFR L833V/H835L rare gene compound mutation and summarized the characteristics of this group of patients and the effect of applying different kinds of EGFR-TKIs treatment..
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 18 mutation • EGFR L833V + EGFR H835L • EGFR H835L • EGFR L833V
    |
    Gilotrif (afatinib)
    over1year
    Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report. (PubMed, Anticancer Drugs)
    The patient remain benefitted for osimertinib monotherapy over 22 months with no disease progression. Our case firstly provided clinical evidences of first-line osimertinib therapy in lung cancer patients with rare L833V/H835L EGFR mutation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    EGFR mutation • EGFR L833V + EGFR H835L • EGFR H835L • EGFR L833V
    |
    Tagrisso (osimertinib)